Do you want to read an article? Please log in or register.
Regression patterns of uveal melanoma after iodine-125 plaque brachytherapy
Ocular Oncology
Related content
Ocular Oncology
Ruthenium-106 versus iodine-125 plaque brachytherapy of 571 choroidal melanomas with a thickness of ≥5.5 mm
Br J Ophthalmol.
Filì M, Trocme E, Bergman L, See TRO, André H, Bartuma K, Girnita L, All-Eriksson C, Seregard S, Stålhammar G
doi: 10.1136/bjophthalmol-2018-313419.
Macular DiseasesOcular OncologyRetinal Diseases
Nomogram for visual acuity outcome after iodine-125 plaque radiotherapy and prophylactic intravitreal bevacizumab for uveal melanoma in 1131 patients
Br J Ophthalmol.
Dalvin LA, Zhang Q, Hamershock RA, Chang M, Yu MD, Mashayekhi A, Shields CL
doi: 10.1136/bjophthalmol-2019-314686.
Ocular Oncology
Effects of plaque brachytherapy and proton beam radiotherapy on prognostic testing: a comparison of uveal melanoma genotyped by microsatellite analysis
Br J Ophthalmol.
Thornton S, Coupland SE, Heimann H, Hussain R, Groenewald C, Kacperek A, Damato B, Taktak A, Eleuteri A, Kalirai H
doi: 10.1136/bjophthalmol-2019-315363.
Ocular Oncology
Impact of uveal melanoma thickness on post-plaque radiotherapy outcomes in the prophylactic anti-vascular endothelial growth factor era in 1131 patients
Clin Exp Ophthalmol.
Yang X, Dalvin LA, Mazloumi M, Chang M, Shields JA, Mashayekhi A, Shields CL
doi: 10.1111/ceo.13758.
COMMENTED
Ocular Oncology
Visual Outcome at 4 Years Following Plaque Radiotherapy and Prophylactic Intravitreal Bevacizumab (Every 4 Months for 2 Years) for Uveal Melanoma: Comparison With Nonrandomized Historical Control Individuals
★ 3
Recommended and commented by
Dr habil. Gábor Márk Somfai, PhD, Faculty Member
doi: 10.1001/jamaophthalmol.2019.5132.
Ocular Oncology
Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition
Eur J Cancer.
Heppt MV, Heinzerling L, Kähler KC, Forschner A, Kirchberger MC, Loquai C, Meissner M, Meier F, Terheyden P, Schell B, Herbst R, Göppner D, Kiecker F, Rafei-Shamsabadi D, Haferkamp S, Huber MA, Utikal J, Ziemer M, Bumeder I, Pfeiffer C, Schäd SG, Schmid-Tannwald C, Tietze JK, Eigentler TK, Berking C
doi: 10.1016/j.ejca.2017.05.038.
Ocular Oncology
Genetic Analysis of Uveal Melanoma in 658 Patients Using the Cancer Genome Atlas Classification of Uveal Melanoma as A, B, C, and D
Ophthalmology.
Vichitvejpaisal P, Dalvin LA, Mazloumi M, Ewens KG, Ganguly A, Shields CL
doi: 10.1016/j.ophtha.2019.04.027.
Ocular Oncology
Intraocular Metastasis in Unilateral Multifocal Uveal Melanoma Without Melanocytosis or Germline BAP1 Mutations
JAMA Ophthalmol.
Durante MA, Walter SD, Paez-Escamilla M, Tokarev J, Decatur CL, Dubovy SR, Schefler AC, Harbour JW
doi: 10.1001/jamaophthalmol.
Ocular Oncology
Multi-Modality Analysis Improves Survival Prediction in Enucleated Uveal Melanoma Patients
Invest Ophthalmol Vis Sci.
Drabarek W, Yavuzyigitoglu S, Obulkasim A, van Riet J, Smit KN, van Poppelen NM, Vaarwater J, Brands T, Eussen B, Verdijk RM, Naus NC, Mensink HW, Paridaens D, Boersma E, van de Werken HJG, Kilic E, de Klein A, for the Rotterdam Ocular Melanoma Study Group.
doi: 10.1167/iovs.18-24818.